ArticleNature communications2019
Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 69 citations in OpenAlex.
- TMEM63B regulates nucleocytoplasmic transport and placental development.Nature communications · 2026Article
- The upregulation of GDF15 is controlled epigenetically by oncogenic TCF19 signaling in human hepatocellular carcinoma.iScience · 2025Article
- Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.Journal of molecular biology · 2025Review
- Research progress of ECT2 and RhoA-related signaling pathways in gynecological tumors.Frontiers in cell and developmental biology · 2025Review
- The Small GTPase Ran Increases Sensitivity of Ovarian Cancer Cells to Oncolytic Vesicular Stomatitis Virus.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Master regulators governing protein abundance across ten human cancer types.bioRxiv : the preprint server for biology · 2024Article
- Proteomic Identification of Small Extracellular Vesicle Proteins LAMB1 and Histone H4 for Prostate Cancer Diagnosis and Risk Stratification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- ROR2/Wnt5a Signaling Regulates Directional Cell Migration and Early Tumor Cell Invasion in Ovarian Cancer.Molecular cancer research : MCR · 2024Article
- B-type Plexins promote the GTPase activity of Ran to affect androgen receptor nuclear translocation in prostate cancer.Cancer gene therapy · 2023Article
- Proteomic Profiling of Fallopian Tube-Derived Extracellular Vesicles Using a Microfluidic Tissue-on-Chip System.Bioengineering (Basel, Switzerland) · 2023Article
- LINC00858 stabilizes RAN expression and promotes metastasis of gastric cancer.Biology direct · 2022Article
- Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.Journal of translational medicine · 2022Article
- The mevalonate pathway promotes the metastasis of osteosarcoma by regulating YAP1 activity via RhoA.Genes & diseases · 2022Article
- Identification of key serum biomarkers for the diagnosis and metastatic prediction of osteosarcoma by analysis of immune cell infiltration.Cancer cell international · 2022Article
- Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.Cell reports · 2021Article
- Glucose starvation suppresses gastric cancer through targeting miR-216a-5p/Farnesyl-Diphosphate Farnesyltransferase 1 axis.Cancer cell international · 2021Article
- AAMP promotes colorectal cancermetastasis by suppressing SMURF2-mediatedubiquitination and degradation of RhoA.Molecular therapy oncolytics · 2021Article
- Developmental programming and lineage branching of early human telencephalon.The EMBO journal · 2021Article
- Article
- Optical manipulation of molecular function by chromophore-assisted light inactivation.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Ran is a nucleocytoplasmic shuttle protein that is involved in cell cycle regulation, nuclear-cytoplasmic transport, and cell transformation. Ran plays an important role in cancer cell survival and cancer progression. Here, we show that, in addition to the nucleocytoplasmic localization of Ran, this GTPase is specifically associated with the plasma membrane/ruffles of ovarian cancer cells. Ran depletion has a drastic effect on RhoA stability and inhibits RhoA localization to the plasma membrane/ruffles and RhoA activity. We further demonstrate that the DEDDDL domain of Ran is required for the interaction with serine 188 of RhoA, which prevents RhoA degradation by the proteasome pathway. Moreover, the knockdown of Ran leads to a reduction of ovarian cancer cell invasion by impairing RhoA signalling. Our findings provide advanced insights into the mode of action of the Ran-RhoA signalling axis and may represent a potential therapeutic avenue for drug development to prevent ovarian tumour metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.